DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1612)

Non-Small-Cell Lung Cancer | Unmet Need | Detailed, Expanded Analysis (US & EU)

Non-Small-Cell Lung Cancer | Unmet Need | Detailed, Expanded Analysis (US & EU)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Despite the wide range of treatment options available, metastatic non-small-cell lung cancer ( NSCLC ) remains a major cause of cancer-related death. For patients with metastatic ( EGFR - and ALK -negative/unknown) NSCLC , chemotherapy is still a mainstay of treatment. However, immune checkpoint inhibitors (Opdivo, Keytruda, and most recently Tecentriq) are revolutionizing the treatment algorithm for this subpopulation. As this market segment continues to evolve at a rapid pace, drug manufacturers must understand the unmet needs associated with the treatment of metastatic NSCLC to identify the opportunities for drug development. We focus on this commercially important subpopulation and assess how current therapies perform on key drug attributes and how these attributes affect medical oncologists’ prescribing decisions. We identify potential hidden opportunities and which emerging therapies (if any) could capitalize upon them. Furthermore, we use conjoint analysis to determine attribute and price trade-offs that surveyed medical oncologists are willing to make when considering treatment options for metastatic NSCLC and simulate the share of preference and likelihood to prescribe of different target product profiles.
Questions Answered:

What are the treatment drivers and goals for metastatic ( EGFR - and ALK -negative/unknown) NSCLC ?
What attributes are key influences, which have limited impact, and which are hidden opportunities?
How do current therapies perform on key treatment drivers and goals for metastatic ( EGFR - and ALK - negative/unknown) NSCLC ?
What are the prevailing areas of unmet need and opportunity in metastatic ( EGFR - and ALK -negative/unknown) NSCLC ?
What trade-offs across different clinical attributes and price are acceptable to and European medical oncologists for a hypothetical new metastatic ( EGFR - and ALK -negative/unknown) NSCLC drug?

Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 60 and 30 European medical oncologists fielded in December 2016.
Key companies: Bristol-Myers Squibb, Merck & Co., Eli Lilly & Co., Roche/Genentech
Key drugs: Opdivo, Keytruda, Alimta, Avastin

  • Pub Date: September 2017
  • Author(s): Joshua Dawkins, M.Pharmacol., PhD

Request report

Related reports:
You may also be interested in: